Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943552 | 1.00 | KMT2A (0.51) | KMT2AMEN1FPR2KDM4EGAA | |
| SCHEMBL23389178 | 1.00 | KMT2A (0.51) | KMT2AMEN1FPR2KDM4EGAA | |
| SCHEMBL23389233 | 0.85 | KMT2A (0.46) | KMT2AMEN1CA1CA2HRH3 | |
| SCHEMBL23389232 | 0.85 | KMT2A (0.46) | KMT2AMEN1CA1CA2HRH3 | |
| SCHEMBL29943544 | 0.82 | DDR1 (0.47) | KMT2AKDM4EGAACA1CA2 | |
| SCHEMBL23389143 | 0.82 | DDR1 (0.47) | KMT2AKDM4EGAACA1CA2 | |
| SCHEMBL23389145 | 0.82 | DDR1 (0.47) | KMT2AKDM4EGAACA1CA2 | |
| SCHEMBL23419189 | 0.81 | FPR2 (0.55) | KMT2AMEN1FPR2KDM4EGAA | |
| SCHEMBL21235453 | 0.80 | KMT2A (0.55) | KMT2AMEN1FPR2HRH3PARP1 | |
| SCHEMBL29991244 | 0.80 | KMT2A (0.55) | KMT2AMEN1FPR2HRH3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | SHANGPHARMA INNOVATION INC. | 2025-08-21 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KMT2A 4587/4885MEN1 4223/4885FPR2 3309/4885 |
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | KMT2A 4587/4885MEN1 4223/4885FPR2 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.